Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. Our ability to fund our projects enables us to execute and deliver on our mission.
Data Provided by Refinitiv. Minimum 15 minutes delayed.

-
February 22, 2023
Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 22, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results.
-
February 22, 2023
- Sustained, elevated expression of alpha-galactosidase A (α-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of
-
February 21, 2023
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. ET to review its fourth quarter and full year 2022
-
November 16, 2022
Brisbane, California, November 16, 2022 – Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022.
Filing date | Form | Description | Filing Group | View |
---|---|---|---|---|
8-K | Report of unscheduled material events or corporate event |
Current Reports
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
8-K | Report of unscheduled material events or corporate event |
Current Reports
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
8-K | Report of unscheduled material events or corporate event |
Current Reports
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
- More events are coming soon.
-
Mar 15, 2023 at 2:05 PM EDT
-
Mar 6, 2023 at 2:50 PM EST